AstraZeneca Pharma's Q4 results show a mix of positives and negatives, leading to fluctuations in its stock price. Meanwhile, keep an eye on Coal India, PhysicsWallah, ONGC, Siemens, and IRCTC for potential market movements.

AstraZeneca Pharma India anticipates a significant 33% revenue increase to INR 22,755.8 Mn by FY26, bolstered by the robust performance of its Oncology and Biopharma divisions, following 11 new regulatory approvals.

AstraZeneca's Q4 earnings reveal a surge in revenue, particularly in the oncology and biopharma sectors. However, heightened costs and the closure of their Bengaluru facility negatively impacted their profit margins.

AstraZeneca Pharma's Q4 EBITDA dropped significantly by 30%, with margins shrinking to 10.5%. This marks a substantial decrease compared to the previous year, highlighting potential challenges in the company's profitability.

AstraZeneca's Q4 profit saw a 23% decrease despite a 20.4% revenue increase, totaling ₹44.8 crores. For the fiscal year 2026, revenue hit ₹2,275.6 crores and the board suggested a dividend of ₹36 per share, causing shares to climb by 2.6% to ₹9,025.

On May 26th, numerous companies such as IRCTC, ONGC, Siemens, AstraZeneca, JK Tyre, Bayer CropScience, EID Parry, Gujarat Fluorochemicals, and GIC India will be releasing their Q4FY26 financial results. Investors eagerly await updates from these firms on their recent performances.

AstraZeneca has received approval to sell Acalabrutinib, a cancer drug, in India. This medication is intended for adults with untreated mantle cell lymphoma when used in combination with BR therapy.

AstraZeneca has received government approval to import the cancer drug Calquence, which is used to treat mantle cell lymphoma, expanding its options for patients in need.

AstraZeneca India's board meeting scheduled for May 26, 2026, will focus on discussing and reviewing their latest results. Stay tuned for updates regarding their performance.

NTPC's Tehri PSP, a renewable power project, is now fully operational, adding to the nation's renewable capacity. Meanwhile, HUDCO and NBCC have signed agreements for urban renewal and real estate development. L&T Realty has acquired IGSL for approximately 1.12 billion rupees, while AstraZeneca eyes a 3.4 billion rupee sale of its Bengaluru plant. Zaggle collaborates with Generali, and Shalby extends its kidney transplant services.

AstraZeneca Pharma India has announced its intention to sell a 64-acre property in Bengaluru for approximately INR 3,400 crores. This sale could mark a significant financial move for the pharmaceutical company.

AstraZeneca has secured government approval to introduce Acalabrutinib tablets into the Indian market, providing additional treatment alternatives for individuals battling specific blood cancers like Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This move will broaden therapeutic options in India.

AstraZeneca's Calquence, a leukemia treatment drug, has been given the green light by India's CDSCO for import, paving the way for its use in battling the disease.